EstoniaTuberculosis profile
Population  2014 1.3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.027 (0.027–0.027) 2.1 (2–2.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.3 (0.2–0.43)
Prevalence  (includes HIV+TB) 0.32 (0.14–0.58) 25 (11–44)
Incidence  (includes HIV+TB) 0.27 (0.24–0.3) 20 (18–23)
Incidence (HIV+TB only) 0.024 (0.021–0.027) 1.8 (1.6–2.1)
         
Case detection, all forms (%) 88 (78–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 19 (14–27) 62 (42–79)
MDR-TB cases among notified pulmonary
TB cases
37 (26–51) 24 (16–31)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 163   22
Pulmonary, clinically diagnosed 29   7
Extrapulmonary 13   2
       
Total new and relapse 236    
Previously treated, excluding relapses 10    
Total cases notified 246    
Among 236 new and relapse cases:
1 (<1%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 175 (107%) 29 (71%) 203
Laboratory-confirmed RR-/MDR-TB cases     50
Patients started on MDR-TB treatment ***     48
TB/HIV 2014 Number (%)
TB patients with known HIV status 238 (97)
HIV-positive TB patients 24 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 19 (79)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (87) 226
Previously treated cases, excluding relapse, registered in 2013 (60) 10
HIV-positive TB cases, all types, registered in 2013 (66) 29
RR-/MDR-TB cases started on second-line treatment in 2012 (76) 50
XDR-TB cases started on second-line treatment in 2012 (33) 3
Laboratories 2014  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 7.6
Drug susceptibility testing (per 5 million population) 7.6
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally  
% Unfunded <1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-24 Data: www.who.int/tb/data